Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 146-151

  Matiasek, L A ^a   Platt, S R ^b   Adams, V ^a   Scase, T J ^c   Keys, D ^b   Miller, J ^a   Adamo, F ^d   Long, S ^e   Matiasek, K ^a,f  

^a ANIMAL HEALTH TRUST   (United Kingdom)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Bay Area Veterinary Specialists ^*  (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Canine; Intracranial meningioma; Ki 67; Survival; VEGF

Indexed keywords

KI 67 ANTIGEN; VASCULOTROPIN A;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; MENINGIOMA; METABOLISM; PHYSIOLOGY;

ANIMALS; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; KI-67 ANTIGEN; MENINGIOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349105991     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0235.x     Document Type: Article

References (57)

1. Koestner A, Bilzer T, Fatzer R, et al. Histological Classification of Tumors of the Nervous System of Domestic Animals, Vol. 5, 2nd ed. Washington, DC: Armed Forces Institute of Pathology; 1999:22.
2. Devaprasath A, Chack G. Diagnostic validity of the Ki-67 labelling Index using the MIB-1 monoclonal antibody in the grading of meningioma. Neurol India 2003;51:336-340.
3. Lanzafame S, Torrisi A, Barbagallo G, et al. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningioma with a 6 year mean follow-up. Pathol Res Pract 2000;196:483-488.
4. Takahashi JA, Ueba T, Hashimoto M, et al. The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningioma. Surg Neurol 2004;61:149-155.
5. Ferraraccio F, Accardo M, Giangaspero F, Cuccurullo L. Recurrent and atypical meningioma-a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining. Clin Neuropathol 2003;22:187-192.
6. Hsu DW, Efird JT, Hedley-Whyte ET. MIB-1 (Ki-67) index and transforming growths factor alpha (TGF alpha) immunoreac-tivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 1998;24:441-452.
7. Langford LA, Cooksley CS, de Monte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol 1996;27:350-354.
8. Kalala JP, Caemaert J, De Ridder L. Primary resected men-ingiomas: Relapses and proliferation markers. InVivo 2004;18:411-416.
9. Konstantinidou AE, Pavlopoulos PM, Patsouris E, et al. Expression of apoptotic and proliferation markers in meningioma. J Pathol 1998;186:325-330.
10. Konstantinidou AE, Korkolopoulou P, Kavantzas N, et al. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningioma. Histol Histopathol 2003;18:67-74.
11. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-29.
12. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
13. Castagnaro M, De Maria R, Bozzetta E, et al. Ki-67 as indicator of the post-surgical prognosis in feline mammary carcinoma. Res Vet Sci 1998;65:223-226.
14. Pena LL, Nieto AI, Perez-Alenza D, et al. Immunohisto-chemical detection of Ki-67 and PCNA in canine mammary tumors: Relationship to clinical and pathologic variables. J Vet Diagn Invest 1998;10:237-246.
15. Laprie C, Adabie J, Amardeilh MF, et al. MIB-1 immuno-reactivity correlates with biologic behaviour in canine cutanous melanoma. Vet Dermatol 2001;12:139-147.
16. Kim Y-J, Ketter R, Henn W, et al. Histopathological indicators of recurrence in meningiomas: Correlation with clinical and genetic parameters. Virchows Arch 2006;449:529-538.
17. Abadie JJ, Amardeilh MA, Delverdier ME. Immunohisto-chemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumours from dogs. J Am Vet Med Assoc 1999;215:1629-1634.
18. Roels S, Tilmant K, Ducatelle R. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. J Comp Pathol 1999;121:13-24.
19. Zuccari DA, Santana AE, Cury PM, Cordeiro JA. Immunocytochemical study ofKi-67 as a prognostic marker in canine mammary neoplasia. Vet Clin Pathol 2004;33:23-28.
20. Perez Alenza MD, Pena L, del Castillo N, et al. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 2000;41:287-691.
21. Scase TJ, Edwards D, Miller J, et al. Canine mast cell tumors: Correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006;20:151-158.
22. Segiun B, Besancon MF, McCallan JL, et al. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med 2006;20:933-940.
23. Ettinger SN, Scase TJ, Oberthaler KT, et al. Association of argryrophilic nuleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002). J Am Vet Med Assoc 2006;228:1053-1063.
24. Cantile C, Campani D, Menicagli M, et al. Pathological and immunohistochemical studies of choroid plexus carcinoma of the dog. J Comp Pathol 2002;126:183-193.
25. Zabka TS, Lavely JA, Higgins RJ. Primary intra-axial leiomyosarcoma with obstructive hydrocephalus in a young dog. J Comp Pathol 2004;131:334-337.
26. Long S, Agryle DJ, Nixon C, et al. Telomerase reverse tran-scriptase (TERT) expression and proliferation in canine brain tumours. Neuropathol Appl Neurobiol 2006;32:662-673.
27. Mandara MT, Ricci G, Rinaldi L, et al. Immunohistochem-ical identification and image analysis quantification of oestrogen and progesterone receptors in canine and feline meningioma. J Comp Pathol 2002;127:214-218.
28. Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery 2003;53:639-661.
29. Zadeh G, Guha A. Angiogenesis in nervous system disorders. Neurosurgery 2003;53:1362-1376.
30. Folkman J, D'Amore P. Blood vessel formation: What is the molecular basis? Cell 1996;87:1153-1155.
31. Pistolesi S, Fontanini G, Camacci T, et al. Meningioma-as-sociated brain oedema: The role of angiogenic factors and pial blood supply. J Neurooncol 2002;60:159-164.
32. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109-120.
33. Provias J, Claffey K, delAguila L, et al. Meningiomas: Role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997;40:1016-1026.
34. Beatriz M, Lopes S. Angiogenesis in brain tumors. Microsc Res Tech 2003;60:225-230.
35. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endo-thelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
36. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000;50:71-87.
37. Yamasaki F, Yoshioka H, Hama S, et al. Recurrence of meningiomas. Influence of vascular endothelial growth factor expression. Cancer 2000;89:1102-1110.
38. Platt SR, Scase TJ, Adams V, et al. Vascular endothelial growth factor expression in canine intracranial meningioma and association with patient survival. J Vet Intern Med 2006;20:663-668.
39. Rossmeisl JH, Duncan RB, Huckle WR, et al. Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms. AJVR 2007;68:1239-1245.
40. Dickinson PJ, Roberts BN, Higgins RJ, et al. Expression of receptor tyrosine kinases VEGF-1 (FLT-1), VEGF-2 (KDR), EGFR-1, PDGFRα and c-Met in canine primary brain tumours. Vet Comp Oncol 2006;4:132-140.
41. Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery 2003;53:1362-1376.
42. Folkman J. Clinical applications of angiogenesis research. New Engl J Med 1995;333:1757-1763.
43. Pistolesi S, Boldrini L, Gisfredi S, et al. Angiogenesis in in-tracranial meningiomas: Immunohistochemical and molecular study. Neuropathol Appl Neurobiol 2004;30:118-125.
44. Hattori K, Miyachi S, Kobayashi N, et al. Contralateral meningeal artery supply of paramedian meningiomas. Surg Neurol 2005;64:242-248.
45. Brearley MJ, Jeffery ND, Phillips SM, Dennis R. Hypo-fractionated radiation therapy of brain masses in dogs: A retrospective analysis of survival of 83 cases (1991-1996). J Vet Intern Med 1999;13:408-U2.
46. Aguiar PH, Tsanaclis AM, Tella OI, et al. Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1. Correlation with peritumoural oedema and other clinicoradio-logical and histological characteristics. Neurosurg Rev 2003;26:221-228.
47. Giangaspero F, Doglioni C, Rivano MT, et al. Growth fraction in human brain tumors defined by monoclonal antibody Ki-67. Acta Neuropath (Berlin) 1987;74:179-182.
48. Roggendolf W, Schuster T, Pfeiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropath (Berlin) 1987;73:361-364.
49. Ostertag CB, Volk B, Shibata T, et al. The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours. Acta Neurochir (Wien) 1987;89:117-121.
50. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
51. Theon AP, Lecouteur RA, Carr EA, et al. Influence of tumor cell proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas. J Am Vet Med Assoc 2000;216:701-707.
52. Landberg G, Roos G. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res 1991;51:4570-4574.
53. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with the DNA replication. Exp Cell Res 1986;163:287-293.
54. Bravo R, Macdonald-Bravo H. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: Association with DNA replication sites. J Cell Biol 1987;105:1549-1554.
55. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
56. Machein MR, Kullmer J, Ronicke V, et al. Differential downregulation of vascular endothelial growth factor by dexameth-asone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999;25:104-112.
57. Heiss JD, Papavassiliou E, Merill MJ, et al. Mechanisms of dexamethasone suppression of brain tumor-associated vascular permeability in rats. J Clin Invest 1996;98:1400-1408.